Virus was produced from plasmid-based DNA segments of a common Wuhan strain. The S-gene was site-specifically replaced with a cloned BA.5-based S-gene sequence.
Virus has been produced from plasmid-based DNA segments of a common Wuhan strain. The S-gene was site-specifically replaced with a cloned BA.2-based S-gene sequence.
Virus was produced from plasmid-based DNA segments of a common Wuhan strain. The S-gene was site-specifically replaced with a cloned BA.1-based S-gene sequence.
Infectious supernatant containing LCMV strain Clone 13 with a point mutation at glycoprotein Aa38 (phenylalanine to leucine), resulting in a loss of binding of the otherwise immunodominant and here mutated H-2Db-presente
Infectious supernatant containing LCMV strain Clone 13 with a point mutation at glycoprotein Aa280 (asparagine to aspartic acid), resulting in a loss of binding of the otherwise immunodominant and here mutated H-2Db-pres
Infectious supernatant containing LCMV strain Clone 13 with a point mutation at nucleoprotein Aa400 (asparagine to serine), resulting in a loss of binding of the otherwise immunodominant and here mutated H-2Db-presented
Plasmid contains the entire genome of HIV-1 (NL4-3) with the respective specific mutations in the protease gene. These may confer drug resistance to specific HIV protease inhibitors and have been identified in clinical specimens from individuals with therapeutic failure.
Gp41 recombinant, carrying the "MIF" motif, typical for subtype AE, in the fusion domain of the subtype B prototype NL4-3 - for studying the fusion function
Gp41 recombinant, carrying the "MIF" motif, typical for subtype AE, in the fusion domain of the subtype B prototype NL4-3 - for studying the fusion function.
HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.
HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.
HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.
Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the protease gene, which can confer drug resistance to specific HIV-1 PR inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on PR inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the viral protease gene, which can confer drug resistance to specific HIV-1 protease inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on protease inhibitors with virologic therapy failure.